Columbia Asset Management Increased Its Macquarie Infrastructur (MIC) Holding; Oxford Immunotec Global PLC (OXFD)’s Sentiment Is 1.34

June 19, 2018 - By Marie Mckinney

Oxford Immunotec Global PLC (NASDAQ:OXFD) Logo

Columbia Asset Management increased Macquarie Infrastructur (MIC) stake by 164.36% reported in 2018Q1 SEC filing. Columbia Asset Management acquired 9,130 shares as Macquarie Infrastructur (MIC)’s stock declined 12.54%. The Columbia Asset Management holds 14,685 shares with $542,000 value, up from 5,555 last quarter. Macquarie Infrastructur now has $3.59 billion valuation. The stock increased 0.74% or $0.31 during the last trading session, reaching $42.14. About 537,785 shares traded. Macquarie Infrastructure Corporation (NYSE:MIC) has declined 51.52% since June 19, 2017 and is downtrending. It has underperformed by 64.09% the S&P500. Some Historical MIC News: ; 09/04/2018 – Adam Longo: Breaking right now, the New York Times is reporting the FBI just raided the offices of President Trump’s lawyer Mic; 07/05/2018 – Moab Partners Gratified That ISS Has Recommended Against the Re-Election of Three Current Bd Members of Macquarie Infrastructure Corp; 17/04/2018 – Moab Capital Urges Macquarie Infrastructure Corp. Shareholders to Vote Against the Re-Election of the Board at the Upcoming Annual Meeting; 23/04/2018 – Aligned Energy Announces New Strategic Investment by Macquarie Infrastructure Partners; 16/05/2018 – SHAREHOLER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Macquarie Infrastructure Corporation of Class Action Lawsuit and Upcoming Deadline — MIC; 02/05/2018 – Macquarie Infrastructure 1Q Rev $501.6M; 07/05/2018 – MIC: GLASS LEWIS RECOMMENDS HOLDERS VOTE FOR CO.’S SLATE; 08/03/2018 – MIMUSA Announces Intent to Acquire Additional Shrs of MIC; 21/03/2018 – Gibson Energy Announces the Upcoming Retirement of Clayton Woitas as a Director of the Company and Names John Festival as a Board Nominee; 17/04/2018 – MOAB CAPITAL PARTNERS SAYS MACQUARIE INFRASTRUCTURE CORP’S EXTERNAL MANAGER, MACQUARIE INFRASTRUCTURE MANAGEMENT (USA), “MUST BE DISSOLVED”

Oxford Immunotec Global PLC (OXFD) investors sentiment decreased to 1.34 in Q1 2018. It’s down -0.23, from 1.57 in 2017Q4. The ratio fall, as 39 institutional investors increased or started new positions, while 29 sold and reduced their holdings in Oxford Immunotec Global PLC. The institutional investors in our database now possess: 23.37 million shares, down from 23.93 million shares in 2017Q4. Also, the number of institutional investors holding Oxford Immunotec Global PLC in top ten positions was flat from 2 to 2 for the same number . Sold All: 9 Reduced: 20 Increased: 29 New Position: 10.

New Leaf Venture Partners L.L.C. holds 5.73% of its portfolio in Oxford Immunotec Global PLC for 852,497 shares. Consonance Capital Management Lp owns 2.34 million shares or 2.66% of their US portfolio. Moreover, First Light Asset Management Llc has 1.71% invested in the company for 626,585 shares. The Vermont-based Birchview Capital Lp has invested 1.45% in the stock. Redmile Group Llc, a California-based fund reported 2.47 million shares.

More notable recent Oxford Immunotec Global PLC (NASDAQ:OXFD) news were published by: Globenewswire.com which released: “Oxford Immunotec to Present at the Jefferies 2018 Healthcare Conference” on May 29, 2018, also Globenewswire.com with their article: “Oxford Immunotec Announces Launch of the Accutixâ„¢ Brand” published on May 22, 2018, Globenewswire.com published: “Investor Expectations to Drive Momentum within Oxford Immunotec Global, Financial Engines, Brookfield Property …” on June 05, 2018. More interesting news about Oxford Immunotec Global PLC (NASDAQ:OXFD) were released by: Nasdaq.com and their article: “Oxford Immunotec Announces Data Presentations for T-SPOT®.CMV Test at the 2018 American Transplant Congress” published on June 04, 2018 as well as Nasdaq.com‘s news article titled: “Oxford Immunotec’s T-SPOT®.TB Test Included in the World Health Organization’s First-Ever Essential Diagnostics List” with publication date: May 21, 2018.

Since January 1, 0001, it had 0 insider buys, and 2 insider sales for $74,342 activity.

The stock increased 0.91% or $0.13 during the last trading session, reaching $14.43. About 224,741 shares traded or 66.60% up from the average. Oxford Immunotec Global PLC (OXFD) has risen 0.28% since June 19, 2017 and is uptrending. It has underperformed by 12.29% the S&P500. Some Historical OXFD News: ; 22/05/2018 – OXFORD IMMUNOTEC ANNOUNCES LAUNCH OF THE ACCUTIX™ BRAND; 06/03/2018 – U.S. FDA SAYS APPROVED THE IMUGEN BABESIA MICROTI NUCLEIC ACID TEST FOR DETECTING B. MICROTI DNA IN HUMAN WHOLE BLOOD SAMPLES; 01/05/2018 – Oxford Immunotec Global Adjusts 2018 View To Rev $112M-$115M; 14/05/2018 – RTW Investments LLC Exits Position in Oxford Immunotec; 06/03/2018 – U.S. FDA SAYS APPROVAL OF THE IMUGEN BABESIA MICROTI AFIA AND NAT TESTS WAS GRANTED TO OXFORD IMMUNOTEC INC; 01/05/2018 – Oxford Immunotec Global 1Q Loss $10.3M; 01/05/2018 – Oxford Immunotec Global 1Q Loss/Shr 40c; 14/05/2018 – Broadfin Capital Buys New 1.4% Position in Oxford Immunotec; 06/03/2018 FDA APPROVES OXFORD IMMUNOTEC TESTS FOR BLOOD, PLASMA; 14/05/2018 – Stonepine Capital Buys New 1% Position in Oxford Immunotec

Analysts await Oxford Immunotec Global PLC (NASDAQ:OXFD) to report earnings on August, 7. They expect $-0.24 EPS, up 25.00% or $0.08 from last year’s $-0.32 per share. After $-0.40 actual EPS reported by Oxford Immunotec Global PLC for the previous quarter, Wall Street now forecasts -40.00% EPS growth.

Oxford Immunotec Global PLC, a diagnostics company, focuses on developing and commercializing proprietary tests for the management of immune-regulated conditions. The company has market cap of $373.47 million. The Company’s development activities principally focus on the areas of infectious diseases, transplantation, autoimmune and inflammatory disease, and immune-oncology. It currently has negative earnings. The firm develops its products using its T-SPOT technology platform, which enables the measurement of responses of specific immune cells to inform the diagnosis, prognosis, and monitoring of patients with immune-regulated conditions.

More notable recent Macquarie Infrastructure Corporation (NYSE:MIC) news were published by: Seekingalpha.com which released: “In Case Macquarie Infrastructure Loses More IMTT Customers” on May 29, 2018, also Businesswire.com with their article: “The Law Offices of Howard G. Smith Reminds Investors of June 25th Deadline in the Class Action Lawsuit Against …” published on June 18, 2018, Globenewswire.com published: “SHAREHOLDER ALERT: The Law Offices of Vincent Wong Reminds Investors of Class Actions Involving Macquarie …” on June 18, 2018. More interesting news about Macquarie Infrastructure Corporation (NYSE:MIC) were released by: Prnewswire.com and their article: “Alerian Index Series June 2018 Index Review” published on June 08, 2018 as well as Gurufocus.com‘s news article titled: “Insiders Roundup: MercadoLibre, Discovery” with publication date: June 15, 2018.

Macquarie Infrastructure Corporation (NYSE:MIC) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our daily email newsletter.





Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter:


Recent Posts